RU2017129878A - Фармацевтическая комбинация для применения в лечении пациентов с диабетом 2 типа - Google Patents
Фармацевтическая комбинация для применения в лечении пациентов с диабетом 2 типа Download PDFInfo
- Publication number
- RU2017129878A RU2017129878A RU2017129878A RU2017129878A RU2017129878A RU 2017129878 A RU2017129878 A RU 2017129878A RU 2017129878 A RU2017129878 A RU 2017129878A RU 2017129878 A RU2017129878 A RU 2017129878A RU 2017129878 A RU2017129878 A RU 2017129878A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical combination
- individual
- combination according
- treated
- mmol
- Prior art date
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 7
- 239000008103 glucose Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- XVVOERDUTLJJHN-IAEQDCLQSA-N lixisenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 XVVOERDUTLJJHN-IAEQDCLQSA-N 0.000 claims 4
- 235000012054 meals Nutrition 0.000 claims 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 4
- 229960003105 metformin Drugs 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11166052.8 | 2011-05-13 | ||
| EP11166052 | 2011-05-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013155480/15A Division RU2013155480A (ru) | 2011-05-13 | 2012-05-11 | Фармацевтическая комбинация для применения в лечении пациентов с диабетом 2 типа |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2017129878A true RU2017129878A (ru) | 2019-02-05 |
Family
ID=46052773
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017129878A RU2017129878A (ru) | 2011-05-13 | 2012-05-11 | Фармацевтическая комбинация для применения в лечении пациентов с диабетом 2 типа |
| RU2013155480/15A RU2013155480A (ru) | 2011-05-13 | 2012-05-11 | Фармацевтическая комбинация для применения в лечении пациентов с диабетом 2 типа |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013155480/15A RU2013155480A (ru) | 2011-05-13 | 2012-05-11 | Фармацевтическая комбинация для применения в лечении пациентов с диабетом 2 типа |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20130040878A1 (enExample) |
| EP (1) | EP2709652A1 (enExample) |
| JP (1) | JP6005140B2 (enExample) |
| KR (1) | KR20140041553A (enExample) |
| CN (2) | CN103648519A (enExample) |
| AR (1) | AR086356A1 (enExample) |
| AU (1) | AU2012257780B2 (enExample) |
| BR (1) | BR112013029256A8 (enExample) |
| CA (1) | CA2835336A1 (enExample) |
| MX (1) | MX356728B (enExample) |
| RU (2) | RU2017129878A (enExample) |
| WO (1) | WO2012156312A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3228320T (lt) | 2008-10-17 | 2020-03-10 | Sanofi-Aventis Deutschland Gmbh | Insulino ir glp-1 agonisto derinys |
| US20110118178A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| EP2498801B1 (de) | 2009-11-13 | 2018-01-24 | Sanofi-Aventis Deutschland GmbH | HARMAZEUTISCHE ZUSAMMENSETZUNG UMFASSEND desPro36Exendin-4(1-39)-Lys6-NH2 UND METHIONIN |
| PL2498802T3 (pl) | 2009-11-13 | 2015-06-30 | Sanofi Aventis Deutschland | Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę |
| SI2611458T1 (sl) | 2010-08-30 | 2017-01-31 | Sanofi-Aventis Deutschland Gmbh | Uporaba AVE0010 za izdelavo zdravila za zdravljenje sladkorne bolezni tipa 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| HUE027989T2 (en) | 2011-08-29 | 2016-11-28 | Sanofi Aventis Deutschland | A pharmaceutical composition for use in glycemic control in patients with type 2 diabetes |
| AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
| CN104968341B (zh) * | 2013-01-17 | 2020-06-09 | Vtv治疗有限责任公司 | Glp1r激动剂和二甲双胍的组合及其在制备治疗2型糖尿病和其他障碍的药物中的用途 |
| TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 |
| CA2932875A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| AU2015205620A1 (en) | 2014-01-09 | 2016-07-14 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
| EP3091995B1 (en) | 2014-01-09 | 2024-03-20 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
| CA2970200A1 (en) | 2014-12-12 | 2016-06-16 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| CN115315426B (zh) | 2020-04-01 | 2023-12-12 | 杭州中美华东制药有限公司 | Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法 |
| EP4130005A4 (en) | 2020-04-01 | 2024-04-24 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | CRYSTALLINE FORM A OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THEREOF |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| US20110118178A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| JP5980466B2 (ja) * | 2009-11-13 | 2016-08-31 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インスリングラルギン及びメトホルミンへの付加療法を含む２型糖尿病の治療方法 |
| PL2324853T3 (pl) * | 2009-11-13 | 2016-01-29 | Sanofi Aventis Deutschland | Liksysenatyd jako dodatek do metforminy w leczeniu cukrzycy typu 2 |
| US20110118180A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
-
2012
- 2012-05-10 US US13/468,422 patent/US20130040878A1/en not_active Abandoned
- 2012-05-11 WO PCT/EP2012/058779 patent/WO2012156312A1/en not_active Ceased
- 2012-05-11 AU AU2012257780A patent/AU2012257780B2/en not_active Ceased
- 2012-05-11 RU RU2017129878A patent/RU2017129878A/ru not_active Application Discontinuation
- 2012-05-11 CN CN201280034724.7A patent/CN103648519A/zh active Pending
- 2012-05-11 RU RU2013155480/15A patent/RU2013155480A/ru unknown
- 2012-05-11 KR KR1020137033311A patent/KR20140041553A/ko not_active Ceased
- 2012-05-11 CN CN201810748089.8A patent/CN109045283A/zh active Pending
- 2012-05-11 JP JP2014509759A patent/JP6005140B2/ja not_active Expired - Fee Related
- 2012-05-11 BR BR112013029256A patent/BR112013029256A8/pt not_active Application Discontinuation
- 2012-05-11 MX MX2013013198A patent/MX356728B/es active IP Right Grant
- 2012-05-11 AR ARP120101668A patent/AR086356A1/es unknown
- 2012-05-11 CA CA2835336A patent/CA2835336A1/en not_active Abandoned
- 2012-05-11 EP EP12720196.0A patent/EP2709652A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2709652A1 (en) | 2014-03-26 |
| BR112013029256A8 (pt) | 2018-01-16 |
| JP2014518860A (ja) | 2014-08-07 |
| CN109045283A (zh) | 2018-12-21 |
| KR20140041553A (ko) | 2014-04-04 |
| MX2013013198A (es) | 2014-02-20 |
| CN103648519A (zh) | 2014-03-19 |
| AU2012257780B2 (en) | 2017-06-01 |
| MX356728B (es) | 2018-06-12 |
| AR086356A1 (es) | 2013-12-04 |
| RU2013155480A (ru) | 2015-06-20 |
| US20130040878A1 (en) | 2013-02-14 |
| BR112013029256A2 (pt) | 2016-11-29 |
| JP6005140B2 (ja) | 2016-10-12 |
| CA2835336A1 (en) | 2012-11-22 |
| WO2012156312A1 (en) | 2012-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017129878A (ru) | Фармацевтическая комбинация для применения в лечении пациентов с диабетом 2 типа | |
| RU2013155473A (ru) | Фармацевтическая комбинация для применения для индуцирования потери массы тела у субъектов с диабетом 2 типа или/и для предотвращения набора массы тела у субъектов с диабетом 2 типа | |
| RU2014121386A (ru) | Протокол лечения диабета 2 типа | |
| RU2014111821A (ru) | Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа | |
| RU2013155474A (ru) | Ликсисенатид и метформин для лечения диабета типа 2 | |
| RU2013114376A (ru) | Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа | |
| RU2013155481A (ru) | Ликсисенатид в качестве дополнительной терапии к базальному инсулину при диабете 2 типа | |
| RU2013140403A (ru) | Предотвращение гипогликемии у пациентов с сахарным диабетом 2 типа | |
| Russcher et al. | The role of melatonin treatment in chronic kidney disease | |
| CN1042895C (zh) | 治疗吸毒者戒断综合症及脱瘾的药物组合物 | |
| RU2012123739A (ru) | Фармацевтическая композиция, содержащая агонист гпп-1 и метионин | |
| RU2013148014A (ru) | Профилактика гипогликемии у пациентов с сахарным диабетом 2 типа | |
| JP2017538705A5 (enExample) | ||
| JP2018503644A5 (enExample) | ||
| JP2018509419A5 (enExample) | ||
| Smolensky et al. | Biological rhythms, drug delivery, and chronotherapeutics | |
| CN103919775A (zh) | 9-去甲基小檗碱在制备降血糖药物中的应用 | |
| WO2019227764A1 (zh) | 一种mln4924在制备治疗糖尿病和/或肥胖药物的新用途 | |
| CN102872062A (zh) | 一种治疗或预防肥胖症以及代谢综合症的药物组合物 | |
| US8226990B2 (en) | Composition for treatment of diabetes mellitus and a preparation and an use thereof | |
| JP2011105610A5 (enExample) | ||
| CN105106221B (zh) | 一种染料木素铬配合物在治疗糖尿病的医用用途 | |
| Schwarz | Inflammation as a factor of the pathogenesis of insulin resistance and type 2 diabetes | |
| CN111067910B (zh) | 一种用于预防和治疗糖尿病的药物组合物及其应用 | |
| Thammakumpee et al. | Noncardiogenic pulmonary edema induced by sublingual buprenorphine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20200825 |